Rehab Cognitive denied as experimental or investigational by UnitedHealthcare?
An experimental denial requires the appeal to cite the FDA approval (if any), peer-reviewed phase III data, and the recognised specialty-society guideline that supports the treatment for your indication.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What UnitedHealthcare typically requires
UnitedHealthcare's specific coverage criteria for rehab cognitive are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The UnitedHealthcare angle on Rehab Cognitive
## Why UnitedHealthcare Denied Your Cognitive Rehabilitation as Experimental
UnitedHealthcare classifies a service as experimental or investigational when its internal evidence-review process concludes that the clinical evidence base is not sufficient to establish that the specific cognitive rehabilitation approach is proven safe and effective for your documented diagnosis. This can affect newer protocol-based cognitive training programs, computer-assisted cognitive rehabilitation, or structured interventions for specific diagnoses (such as mild traumatic brain injury, chemotherapy-related cognitive effects, or early neurocognitive disorders) that UHC's policy has not yet recognized as covered. These denials are legally contestable — UHC's internal evidence standards can lag behind current clinical practice, and external reviewers apply current standards, not just the insurer's policy.
## Your Right to Appeal
- Internal appeal: File a written internal appeal within the deadline on your denial letter. Request the specific medical policy, the clinical criteria used, and the evidence review on which UHC based its investigational determination.
- External review (ACA §2719): Experimental and investigational denials are explicitly eligible for IRO external review under federal law. File for external review within approximately four months of your final internal denial. An independent clinician — not affiliated with UHC — will evaluate your case against current medical standards.
- Expedited review: Available for urgent conditions, with a decision typically required within 72 hours.
- ERISA §503: Employer-sponsored plan members retain full-and-fair review rights. Courts have found that an insurer's "investigational" classification does not automatically satisfy the full-and-fair review standard when current clinical literature supports the intervention.
## Documentation to Gather
1. Diagnosis and cognitive assessment: A current neuropsychological evaluation or formal cognitive assessment documenting the specific deficits, their clinical origin, severity, and functional impact on daily activities and work or school capacity. 2. Clinical literature: Ask your provider or the rehabilitation program to compile peer-reviewed studies and current position statements from recognized medical organizations (such as relevant brain injury rehabilitation societies, neurological associations, or cognitive rehabilitation specialty organizations) supporting the specific intervention for your diagnosis. 3. Prior treatment history: Documentation of other approaches tried and their outcomes, demonstrating that this rehabilitation program is not a first-line experimental choice but a considered clinical decision. 4. Prescriber or specialist medical-necessity letter: A letter from a referring neurologist, neuropsychologist, or rehabilitation medicine specialist citing the applicable guideline organization, distinguishing UHC's evidence review from current published standards, and explaining the individualized clinical basis for the treatment.
## Criteria-Mapping Strategy
Obtain the full text of UHC's medical policy for cognitive rehabilitation (search UHC's public Coverage Determination Guidelines). Identify every element of the "investigational" classification. For each element, prepare a written response citing current peer-reviewed literature or society guidance that addresses it. The external review process is your most powerful tool here: IRO reviewers are required to apply current clinical standards, and a well-documented case showing that recognized medical organizations support the intervention for your specific diagnosis frequently results in reversal of an experimental denial.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →Related appeal guides
- UnitedHealthcare denied as experimental or investigational of ABA Autism
- UnitedHealthcare denied as experimental or investigational of Amphetamine Stimulant
- UnitedHealthcare denied as experimental or investigational of Amphetamine Stimulant Prodrug
- UnitedHealthcare denied as experimental or investigational of Anti Amyloid Leqembi